Fig. 3.

Sorafenib enhances DHA’s cytotoxicity in DU-145, MCF7, and MDA-MB-231 cancer cells. Cells were treated with Sorafenib and/or DHA for 48 h and cell viability was determined by the MTS assay (n = 3, means ± SEM, *p < 0.01)